| アブストラクト | BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used due to their profound efficacy in glycemic control and weight management. Real-world observations have revealed potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs. This study aimed to comprehensively investigate and characterize these neuropsychiatric AEs with GLP-1RAs. METHODS: We analyzed GLP-1RA adverse reaction reports using the FDA Adverse Event Reporting System database. Disproportionality analysis using reporting odds ratio (ROR) identified eight categories of neuropsychiatric AEs associated with GLP-1RAs. We conducted descriptive and time-to-onset (TTO) analyses and explored neuropsychiatric AE signals among individual GLP-1RAs for weight loss and diabetes mellitus (DM) indications. RESULTS: We identified 25,110 cases of GLP-1RA-related neuropsychiatric AEs. GLP-1RAs showed an association with headache (ROR 1.74, 95% confidence interval [CI] 1.65-1.84), migraine (ROR 1.28, 95%CI 1.06-1.55), and olfactory and sensory nerve abnormalities (ROR 2.44, 95%CI 1.83-3.25; ROR 1.69, 95%CI 1.54-1.85). Semaglutide showed a moderate suicide-related AEs signal in the weight loss population (ROR 2.55, 95%CI 1.97-3.31). The median TTO was 16 days (interquartile range: 3-66 days). CONCLUSIONS: In this study, we identified eight potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs and, for the first time, detected positive signals for migraine, olfactory abnormalities, and sensory abnormalities. We also observed positive suicide-related signals of semaglutide, in weight loss population. This study provides a reliable basis for further investigation of GLP-1RA-related neuropsychiatric AEs. However, as an exploratory study, our findings require confirmation through large-scale prospective studies. |
|---|
| ジャーナル名 | European psychiatry : the journal of the Association of European Psychiatrists |
|---|
| Pubmed追加日 | 2025/2/4 |
|---|
| 投稿者 | Lu, Wenchao; Wang, Shihan; Tang, Huilin; Yuan, Tao; Zuo, Wei; Liu, Yuling |
|---|
| 組織名 | Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union;Medical College, Beijing, China.;Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of;Medical Sciences and Peking Union Medical College, Beijing, China.;Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of;Health, Peking Union Medical College Hospital, Chinese Academy of Medical;Sciences and Peking Union Medical College, Beijing, China.;Department of Pharmaceutical Outcomes and Policy, University of Florida College;of Pharmacy, Gainesville, FL, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39901452/ |
|---|
